- Home
- BBT vs IMNM Comparison
BBT vs IMNM Comparison
Compare BBT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBT | IMNM |
|---|---|---|
| Founded | 1846 | 2006 |
| Country | United States | United States |
| Employees | 2050 | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BBT | IMNM |
|---|---|---|
| Price | $31.70 | $23.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $33.25 | $32.80 |
| AVG Volume (30 Days) | 616.7K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $77.88 | N/A |
| Revenue Next Year | $4.31 | $1,127.34 |
| P/E Ratio | $29.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.81 | $7.15 |
| 52 Week High | $32.83 | $27.65 |
Technical Indicators
Market Signals| Indicator | BBT | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 54.07 |
| Support Level | $29.17 | $19.23 |
| Resistance Level | $32.09 | $27.14 |
| Average True Range (ATR) | 0.69 | 1.03 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 56.91 | 54.00 |
Price Performance
Historical ComparisonAbout BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.